Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511551 | 1.00 | TDP1 (0.39) | TDP1TSHRKDM6BKDM5CEGLN1 | |
| SCHEMBL20511550 | 1.00 | TDP1 (0.39) | TDP1TSHRKDM6BKDM5CEGLN1 | |
| SCHEMBL20511536 | 1.00 | TDP1 (0.39) | TDP1TSHRKDM6BKDM5CEGLN1 | |
| SCHEMBL20511568 | 0.80 | EGLN1 (0.39) | TSHRKDM6BKDM5CEGLN1PHF8 | |
| SCHEMBL19105492 | 0.78 | TDP1 (0.40) | TDP1TSHRCYP3A4MAPT | |
| SCHEMBL15066277 | 0.78 | EGLN1 (0.38) | TSHRKDM6BKDM5CEGLN1PHF8 | |
| SCHEMBL4676368 | 0.78 | TDP1 (0.44) | TDP1TSHRPKMSMN1; SMN2LMNA | |
| SCHEMBL7814035 | 0.78 | TDP1 (0.44) | TDP1TSHRPKMSMN1; SMN2CYP3A4 | |
| SCHEMBL30104611 | 0.78 | TDP1 (0.40) | TDP1TSHRCYP3A4MAPT | |
| SCHEMBL9561313 | 0.77 | TDP1 (0.46) | TDP1TSHRSMN1; SMN2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3600324-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
| CN-110662543-A | Medicaments and compositions for treating ocular diseases | 灰色视觉公司 | 2020-01-07 | — | — | CN | disclosed |
| WO-2018175922-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | TDP1 564/4885TSHR 2548/4885KDM6B 3228/4885 |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | TDP1 564/4885TSHR 2548/4885KDM6B 3228/4885 |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | TDP1 564/4885TSHR 2548/4885KDM6B 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.